BackTable Tumor Board

A multidisciplinary podcast for healthcare professionals who provide cancer care!

[BackTable Tumor Board @_backtableONC]

Can an "unresectable" pancreatic tumor actually be downstaged to surgery?

On Ep. 62, @ZTBerman, Dr. Rebekah White, and @MV_Sherer discuss changing the paradigm for locally advanced pancreatic cancer.

We dive into how tumor biology matters more than anatomy, the shift toward SBRT dose escalation in the triangle volume, the application of IRE NanoKnife, and the future of KRAS inhibitors.

Listen here: https://t.co/7g45FcOoJf

#PancreaticCancer #Oncology #TumorBoard #ONC62

[BackTable Tumor Board @_backtableONC]

Excited to support this @Onco_Nexus Academic & Community Oncology Panel during @ASCO this year. Looking forward to conversations bringing together perspectives across lung, breast, GI, and GU oncology as new data continues to shape cancer care across both academic and community settings.

These are always some of the most valuable discussions coming out of ASCO each year.

Register to attend in person or join the live stream: https://t.co/qt92hShtkq
📍 Congress Plaza Hotel & Convention Center, May 29th | 6:00-9:15 PM

#ASCO26 #Oncology #CancerResearch

[BackTable Tumor Board @_backtableONC]

In this @BTWomensHealth x Tumor Board crossover episode, Dr. Mona Guo (@xmGuo) and Dr. Marcia Ciccone are joined by USC radiation oncologist and brachytherapy director Dr. Andrew Lim to discuss how modern radiation advancements are shaping gynecologic cancer care.

The conversation covers definitive and adjuvant radiation therapy, brachytherapy techniques, toxicity management, and how multidisciplinary collaboration helps tailor treatment for each patient.

🎧 Listen now: https://t.co/CKYpuX9aFs

#GynecologicOncology #RadiationOncology #Brachytherapy #ONC61

[BackTable Tumor Board @_backtableONC]

3 things Dr. Kate Baker is watching closely at #ASCO26 this year 👀

• RASolute 302 evaluating daraxonrasib in KRAS-mutated pancreatic cancer
• HARMONi-6 and the continued development of ivonescimab in lung cancer
• New ADC sequencing and combination data across solid tumors

One of the most exciting parts of ASCO each year is seeing how quickly emerging science shapes real-world oncology conversations across both academic and community care settings.

What presentations or abstracts are highest on your watch list this year?

#ASCO #Oncology #CancerResearch #LungCancer #PancreaticCancer #MedEd

[BackTable Tumor Board @_backtableONC]

Managing side effects may be the key to maximizing PARP inhibitor benefit.

Drs. Neeraj Agarwal & Arun Azad join Dr. Alan Tan to discuss PARP inhibitors in mCRPC, including side effect management, molecular testing, treatment sequencing, and the real-world barriers preventing patients from reaching later-line therapies.

🎧 Listen to Episode 60 in the BackTable app: https://t.co/itZDrCcvhC

This podcast is supported by an educational grant from Pfizer.

#ONC60 #UrologicOncology #ProstateCancer #PARPInhibitor #MedicalOncology

[BackTable Tumor Board @_backtableONC]

What if there was an effective treatment for hepatocellular carcinoma (HCC) that combines systemic immunotherapy with liver-directed therapies like Y90?

In this final episode of the BackTable 2026 HCC Creator Weekend™, Dr. Lingling Du, Dr. A. Craig Lockhart, and Dr. Jon Mizrahi discuss what's next for the HCC landscape as it continues to evolve. What new targets and strategies are set to shape clinical practice in the near future?

Listen to the full episode here: https://t.co/wy06Kf0ZTb

#HepatocellularCarcinoma #HCC #Immunotherapy #TargetedTherapy #ONC59

[BackTable Tumor Board @_backtableONC]

What comes after first-line immunotherapy in advanced hepatocellular carcinoma (HCC)?

From tyrosine kinase inhibitor dosing to the limited role of next-generation sequencing, the following episode of the BackTable 2026 HCC Creator Weekend™ breaks down the complexities of second-line decision-making.

Listen here: https://t.co/jFBR1Q7ewt

#HCC #MedicalOncology #SecondLine #HCCCreatorWeekend #ONC58

[BackTable Tumor Board @_backtableONC]

How did a single trial in 2020 overturn 10 years of standard care in #HCC?

On TB57, Dr. John Rahi, Dr. Craig Lockhart, and Dr. Lingling Du review the shift from TKIs to IO combinations. Check out the long-term survival "tails" that are changing the prognosis for advanced liver cancer.

Listen here: https://t.co/12y8TQW3vk

#Oncology #LiverCancer #Immunotherapy #ONC57

[BackTable Tumor Board @_backtableONC]

Creator Weekend in Nashville is in the books!

Four new episodes recorded, big conversations captured, and a weekend focused on advancing NMIBC care through multidisciplinary collaboration.

🎙️ Topics included:
• Intravesical therapy clinic models
• Shared decision-making
• Risk stratification
• Toxicity triage and supportive care

Excited to share these episodes soon.

#BTCreatorWeekend #UrologicOncology #BladderCancer

[BackTable Tumor Board @_backtableONC]

The BackTable App brings together expert conversations, courses, case discussions, and more - all in one place!

Already listening?
Download the BackTable App: https://t.co/1MLH73jxt9

#MedEd #ClinicalLearning

[BackTable Tumor Board @_backtableONC]

Explore how tumor biomarkers enable personalized breast cancer treatment while helping reduce financial toxicity in precision medicine.

In this new episode of BackTable Tumor Board, Dr. Jessica Treviño Jones and Dr. Lindsay Peterson cover how genomic testing, technological advances, current research, and patient education inform treatment selection for both early-stage and metastatic breast cancer.

Tune in for the full episode here: https://t.co/AhMUUevL7Q
Or visit https://t.co/17S8yff2Th

#BreastCancer #MetastaticBreastCancer #MedicalOncology #PrecisionMedicine #Biomarkers #ONC56

[BackTable Tumor Board @_backtableONC]

How will the latest colorectal cancer data change practice?

At the 2026 ASCO GI Symposium in San Francisco, trials like BREAKWATER, COMMIT, ATOMIC, and CHALLENGE are redefining treatment strategies.

On the latest BackTable Tumor Board episode, Dr. Shruti Patel and Dr. Jun Gong break down what these trials reveal about where colorectal cancer management is headed next.

Listen here: https://t.co/SbH0PfsH3n

or visit https://t.co/pszxGb7vye

#ColorectalCancer #2026GIASCO #MedicalOncology #Phase3ClinicalTrials #ONC55

[BackTable Tumor Board @_backtableONC]

You know BackTable. Now make it yours.

Inside the app:
- A For You feed built around your specialty
- Search across clinical topics
- Real clinical case discussions
- And more

Download the BackTable App: https://t.co/JQouFHeG83

[BackTable Tumor Board @_backtableONC]

A patient with just two progressing lesions. Do you start systemic therapy or target locally?

With the examples of a few patient cases, Drs. Ryan Funk and Dustin Boothe break down how they approach isolated progression (treat locally with radiation) and widespread progression (escalate to radiopharmaceuticals like Pluvicto) while limiting patient toxicity.

Another aspect to consider is looking at the whole patient and their quality of life when managing the systemic therapy space.

Watch the full episode: https://t.co/m9P4xXNAsD

This podcast is supported by Varian Theranostics.

#Radiopharmaceuticals #RadiationOncology #Theranostics #Oncology #TB50

[BackTable Tumor Board @_backtableONC]

“You need to be curious. You need to be ambitious and not be afraid to think critically.” - Dr. Riad Salem

Dr. Riad Salem joins Dr. Tyler Sandow and Dr. Juan Gimenez for a conversation around the moments, decisions, and lessons that shaped his career and the field of Interventional Oncology.

🎧 Available now, only in the BackTable App

Download now and listen - https://t.co/B81YhpxoRD

#VI632 #Y90 #InterventionalRadiology #HCC #InterventionalOncology

[BackTable Tumor Board @_backtableONC]

Jun Gong and Tyler Stewart discuss how KEYNOTE-B15 and KEYNOTE-905 are redefining bladder cancer care. With EVP becoming the first non-platinum regimen to outperform cisplatin, the curative window for MIBC is shifting.\

Listen here: https://t.co/vIsNPOWutF

#BladderCancer #Oncology #ONC54 #ASCOGU26 #MedTwitter

[BackTable Tumor Board @_backtableONC]

You’ve listened to BackTable.

Now experience it in a whole new way.

Inside the app:
- A For You feed personalized to your specialty
- Clinical search across real-world topics
- Real cases from practicing physicians

The next chapter of BackTable starts here!

Download the BackTable App: https://t.co/ltXEa02vJt

[BackTable Tumor Board @_backtableONC]

Dr. Ryan Funk breaks down how radiopharmaceutical therapies are reshaping the radiation oncologist’s role in community practice—from broader toxicity management to deeper multidisciplinary collaboration.

As radiopharmaceuticals move earlier in treatment pathways, radiation oncologists are increasingly co-managing longitudinal patient care in addition to delivering targeted therapy.

Watch the full episode on the BackTable app: https://t.co/m9P4xXNAsD

This podcast is supported by Varian Theranostics.

#Radiopharmaceuticals #RadiationOncology #Theranostics #OncologyCare #VarianTheranostics #TB50

[BackTable Tumor Board @_backtableONC]

ADCs are redefining the breast cancer landscape, but with great efficacy comes the need for better monitoring. In our latest episode, Dr. Kate Baker & Dr. Sara Nunnery break down HER2-low vs. Ultralow, ILD risk & steroid protocols, and next-gen targets.

Listen now: https://t.co/DXHPWF54qK

#ONC52 #BreastCancer #HER2 #Oncology #ADCs